胃癌患者血清可溶性FasL的变化及意义

Change and significance of soluble Fas ligand in patients with gastric cancer

应用双抗体夹心酶联免疫吸附法(ELISA)检测45例胃癌患者血清中可溶性FasL(sFasL)水平,并取30例健康献血员为对照。结果显示,胃癌患者术前血清sFasL为(15.24±1.25)μg/L,30例健康献血员sFasL病理为(4.21±1.13)μg/L。两组比较P<0.01。胃癌患者术前血清sFasL含量[(15.24±1.25)μg/L]显著高于术后(5.36±1.19)μg/L],P <0.01,且分期越高、分化程度越低、有淋巴结转移、肿瘤直径>3cm者,术前血清sFasL越高。提示胃癌患者血清中含有sFasL,且sFasL在胃癌免疫逃逸、反击机制中起重要作用;术前胃癌血清中sFasL水平可作为术后随访和判断预后的一个重要指标。

To determine the concentration of soluble Fas ligand(sFasL) and its clinical significance in gastriccancer patients,sera of 45 gastric cancer patients and 30 healthy volunteers were collected. ELISA was used todetect the level of sFasL in the sera. Clinical data of gastric cancer pantinets were also obtained. The resultsshowed that the concentration of sFasL in sera of gastric cancer patients before operation and healthy volunteerswere (15. 24±1. 25)μg/L and (4. 21±1. 13)μg/L respectively. The former was si...